¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"tumor associated rejection antigen"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
¿µ¹® brain tumor ÇÑ±Û ³úÁ¾¾ç
¼³¸í   
  ³úÁ¾¾çÀ̶õ ³ú¿Í ³úÁ¶Á÷¿¡¼­ »ý±ä Á¾¾çÀ» ÁöĪÇϴ ¸»ÀÌ´Ù. ±×·¯³ª ´ë°³ ³ÐÀº Àǹ̷Π»ç¿ëÇÒ °æ¿ì¿¡´Â ¸Ó¸®»À¼ÓÀÇ °ø°£ÀΠµÎ°³°­¼Ó¿¡ »ý±â´Â ¸ðµç Á¾¾çÀ» À̸£´Â ¸»·Î »ç¿ëµÈ´Ù.
  
  ³úÁ¾¾çÀº ÇÑÁ¤µÈ °ø°£ÀΠµÎ°³°­¿¡¼­ ¹ß»ýÇϹǷΠÁ¾¾çÀÌ ±×´ÙÁö Å©Áö ¾Ê¾Æµµ Á¤»óÀûÀΠÁ¶Á÷À» ¾Ð¹ÚÇϰԠµÇ°í, µÎ°³°­³»ÀÇ ¾Ð·ÂÀ» ³ôÀδÙ. ÀÌ·± Æ¯Â¡¿¡ ÀÇÇØ¼­ ³úÁ¾¾çÀÇ Áõ»óÀº ´Ù¸¥ Á¾¾ç°ú ´Þ¸®, Á¾¾ç ±× ÀÚüÀÇ Áõ»óº¸´Ùµµ µÎ°³³»¾Ð»ó½Â°ú Á¤»óÁ¶Á÷ÀÇ ¾Ð¹Ú¿¡ ÀÇÇÑ Áõ»óÀÌ ¸¹´Ù. µÎ°³³»¾Ð(³ú¾Ð)ÀÇ »ó½Â¿¡ ÀÇÇÑ Áõ»óÀ¸·Î´Â µÎÅë, ±¸ÅäµîÀÌ ÀÖÀ¸¸ç, Áö¼ÓÀûÀΠ³ú¾Ð»ó½Â¿¡ ÀÇÇØ¼­ À¯µÎºÎÁ¾(papilledema)ÀÌ °üÂûµÇ±âµµ ÇÑ´Ù. ±×¸®°í Á¤»óÀûÀΠ³úÁ¶Á÷ÀÇ ¾Ð¹Ú°ú Á¾¾çÀÌ »ý±ä ºÎÀ§ÀÇ ±â´ÉÀÇ °áÇÕ¿¡ ³úÀÇ ±× ºÎºÐ¿¡ ÇØ´çÇϴ ±â´ÉÀÇ »ó½ÇÀ» º¸°ÔµÈ´Ù.
¿µ¹® epithelial tumor ÇÑ±Û »óÇǼºÁ¾¾ç
¼³¸í   
  Á¤»ó »ç¶÷ÀÇ Á¶Á÷Àº Ã¼Ç¥¸éÀ» µ¤´Â ¿ªÇÒÀ» Çϴ Á¶Á÷°ú, ÁַΠ¹ß»ý±âÀÇ Á߹迱¿¡¼­ ºÐÈ­ÇÑ °£¿±Á¶Á÷¿¡¼­ À¯·¡Çϴ °áÇÕÁ¶Á÷, »À, ¿¬°ñ, Áö¹æ, ±ÙÀ°, Ç÷°ü µîÀÇ Á¶Á÷ÀÇ µÎ °èÅëÀ¸·Î ³ª´­ ¼ö ÀÖ´Ù. ÀüÀÚ¸¦ »óÇǼº Á¶Á÷, ÈÄÀÚ¸¦ ºñ»óÇǼº Á¶Á÷À̶ó Çϸ砱נ°¢°¢À» ±¸¼ºÇϴ ¼¼Æ÷¸¦ »óÇǼº ¼¼Æ÷, ºñ»óÇǼ¼Æ÷¶ó ÃÑĪÇÑ´Ù. »óÇǼº ¼¼Æ÷¿¡¼­ ±â¿øÇϴ Á¾¾çÀÌ »óÇǼº Á¾¾çÀ̸ç, ±ÙóÀÇ Á¶Á÷À¸·Î Ä§Åõ³ª Ç÷·ù, ¸²ÇÁÀÇ Á¶Á÷À» Å¸°í ¿ø°Å¸®ÀÇ Àå±â·Î À̵¿ÇÏÁö ¾Ê´Â ¾ç¼ºÁ¾¾ç¿¡´Â ¼±Á¾, À¯µÎÁ¾ µîÀÌ ÀÖ°í ¾ç¼º°ú ¹Ý´ë·Î ±ÙóÀÇ Á¶Á÷À¸·Î Ä§Åõ, ¿ø°ÝÀå±â·Î ÀüÀÌÇϴ ¾Ç¼ºÁ¾¾çÀ» ¸ðµÎ ÅëĪÇÏ¿© ¾ÏÁ¾(carcinoma)À̶ó°í ÇÑ´Ù.
¿µ¹® medullary tumor ÇÑ±Û ¼öÁú¼º Á¾¾ç
¼³¸í   
  ¾ÏÀÇ º´¸®ÇÐÀûÀΠºÐ·ùÁß Çϳª. ¿©·¯ ±â°üÀÇ ¾Ï¿¡¼­ ³ªÅ¸³ª´Âµ¥ ÁַΠ°©»ó»ù¾ÏÀ̳ª À¯¹æ¾Ï¿¡¼­ º¸ÀδÙ.
¿µ¹® malignant tumor ÇÑ±Û ¾Ç¼ºÁ¾¾ç
¼³¸í   
  Á¤»óÀûÀΠÁ¶Á÷ ¼¼Æ÷°¡ °¢Á¾ ¹°¸®Àû-È­ÇÐÀû-»ý¹°ÇÐÀûÀΠ¹ß¾Ï ¹°ÁúÀÇ Àۿ렶Ǵ ¿äÀο¡ ÀÇÇØ µ¹¿¬º¯À̸¦ ÀÏÀ¸ÄѼ­ Çü¼ºµÇ´Â Á¾¾ç. ¹«Á¦ÇÑÀÇ ¼¼Æ÷ºÐ¿­·Î ¸Å¿ì ¿Õ¼ºÇϰԠÁõ½ÄÇÏ¿© ÁÖÀ§Á¶Á÷À» ÆÄ±«-ħ½ÄÇÑ´Ù. ¶Ç ¾î¶² È­Çй°ÁúÀ» ³»¾î ÁÖÀ§ÀÇ Á¶Á÷¼¼Æ÷¸¦ Ä§ÇØÇÒ »Ó¸¸ ¾Æ´Ï¶ó, Ç÷°ü ¹× ¸²ÇÁ°üÀ» µû¶ó ÀüÀÌÇÏ¿© Àü½ÅÀÇ Ä«ÄʽþƸ¦ÀÏÀ¸ÄÑ Á×À½À» ÃÊ·¡ÇÑ´Ù. »óÇǼºÀΠ°ÍÀ» ¾ÏÁ¾À̶ó Çϰí, ºñ»óÇǼºÀΠ°ÍÀ» À°Á¾À̶ó ÇÑ´Ù.
¿µ¹® benign tumor ÇÑ±Û ¾ç¼ºÁ¾¾ç
¼³¸í   
  ¹ßÀ°¼Óµµ°¡ ¿Ï¸¸ÇÏ¿© ¼ºÀå¿¡ ÇѰ谡 ÀÖ°í, ÁÖÀ§¿ÍÀÇ °æ°è°¡ ¸íÈ®Çϸç, ´Ù¸¥ Á¶Á÷À¸·Î ÆÛÁöÁö ¾ÊÀ¸¸ç, Ä§À±À̳ª ÀüÀ̸¦ ÀÏÀ¸Å°Áö ¾Æ´ÏÇϴ Á¾¾ç. ¼¶À¯Á¾À̳ª Áö¹æÁ¾ µûÀ§°¡ ÀüÇüÀûÀΠ¿¹ÀÌ´Ù. ¾ç¼ºÁ¾¾çÀº Á¾¾çÀÌ Á¸ÀçÇÑ´Ù°í Çصµ 1Â÷ÀûÀ¸·Î ¼÷ÁÖÀÇ »ý¸íÀ» À§ÇùÇϴ ÀÏÀº ¾ø´Ù. ¾ç¼ºÁ¾¾çÀÇ ¹ßÀ°Çü½ÄÀº ÁÖÀ§ÀÇ Á¶Á÷°£¿¡ ¿Õ·¡Çϴ ÀÏÀÌ ¾øÀÌ ÁÖÀ§ÀÇ Á¶Á÷À» ¹Ð¾î³»¸ç Áõ½ÄÇÑ´Ù. ¹ßÀ°¼Óµµ´Â ¿Ï¸¸Çϸç ÀüÀÌÇϰųª ÀýÁ¦ ÈÄ Àç¹ßÇϴ ÀÏÀÌ ±ØÈ÷ µå¹°´Ù. Á¾¾ç¼ººÐÀº º¯ÀÌüÀ̱ä ÇÏÁö¸¸ ¼º¼÷ÇÑ Á¤»ó¼¼Æ÷¿Í °ÅÀÇ ´Ù¸¥ °ÍÀÌ ¾ø´Ù. Àü½Å¿¡ ´ëÇÑ ¿µÇâÀº ¾Ç¼ºÁ¾¾çÀÇ °æ¿ì ¾î´À Á¤µµ ¹ßÀ°ÇßÀ» ¶§ Àü½ÅÀÇ ¿µ¾ç»óŰ¡ ¼Õ»óµÇ¾î Ä«Äʽþư¡ µÇÁö¸¸ ¾ç¼ºÁ¾¾çÀÇ °æ¿ì ÀÌ·± ÀÏÀº °ÅÀÇ ¾ø´Ù. ¾ç¼ºÁ¾¾ç°ú ¾Ç¼ºÁ¾¾çÀÇ ¼º»óÀÇ Â÷ÀÌ¿¡ ¾ö¹ÐÇÑ °æ°è´Â ¾ø°í, °æ°è°æº¯À¸·Î º¸À̴ Á¾¾çµµ ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cell-associated antibody
    ¼¼Æ÷¿¬°üÇ×ü
  • gut-associated lymphatic tissue
    âÀÚ¿¬°ü¸²ÇÁÁ¶Á÷, À忬°ü¸²ÇÁÁ¶Á÷
  • mucosa-associated lymphoid tissue
    Á¡¸·¿¬°ü¸²ÇÁÁ¶Á÷
  • adenomatoid odontogenic tumor
    »ùÁ¾¸ð¾çÄ¡¿ø¼ºÁ¾¾ç
  • adenomatoid tumor
    »ùÁ¾¸ð¾çÁ¾¾ç
  • benign tumor
    ¾ç¼ºÁ¾¾ç
  • collision tumor
    Ãæµ¹Á¾¾ç
  • carcinoid tumor
    Ä«¸£½Ã³ëÀ̵åÁ¾¾ç
  • cystic tumor
    ³¶¼ºÁ¾¾ç
  • desmoid tumor
    µ¥½º¸ðÀ̵åÁ¾¾ç
  • Ewing¡¯s tumor
    À¯À×Á¾¾ç
  • embryonal tumor
    ¹è¾Æ¼ºÁ¾¾ç
  • endodermal sinus tumor
    ³»¹è¿±±¼Á¾¾ç, ³»¹è¿±µ¿Á¾¾ç
  • fecal tumor
    ´ëº¯µ¢ÀÌ, ºÐÁ¾(ÝÐðþ)
  • gastrointestinal autonomic nerve tumor
    À§Ã¢ÀÚÀÚÀ²½Å°æÁ¾¾ç, À§Àå°üÀÚÀ²½Å°æÁ¾¾ç
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antigen receptor
    Ç׿ø¼ö¿ëü
  • antigen-antibody reaction
    Ç׿øÇ×ü¹ÝÀÀ
  • antigen-binding site
    Ç׿ø°áÇÕºÎÀ§
  • tumor suppressor gene
    Á¾¾ç¾ïÁ¦À¯ÀüÀÚ
  • tumor marker
    Á¾¾çÇ¥ÁöÀÚ
  • tumor size
    Á¾¾çÅ©±â
  • tumor
    Á¾¾ç
  • adenomatoid tumor
    »ù¸ð¾çÁ¾¾ç, »ùÁ¾´àÀºÁ¾¾ç
  • benign tumor
    ¾ç¼ºÁ¾¾ç
  • carcinoid tumor
    Ä«¸£½Ã³ëÀ̵åÁ¾¾ç
  • cystic tumor
    ³¶Á¾
  • desmoid tumor
    µ¥½º¸ðÀ̵åÁ¾¾ç
  • endodermal sinus tumor
    ³»¹è¿±±¼Á¾¾ç
  • giant cell tumor
    °Å´ë¼¼Æ÷Á¾
  • glomus tumor
    Å丮Á¾¾ç, »ç±¸Á¾¾ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • rejection
    °ÅºÎ
  • rejection reaction
    °ÅºÎ¹ÝÀÀ
  • specimen rejection
    °Ëü°ÅÀý
  • transplant rejection
    À̽İźÎ
  • tubular rejection fraction ratio
    ÄáÆÏ´¢¼¼°ü°ÅºÎºÐȹ·ü
  • adenomatoid tumor
    »ù¸ð¾çÁ¾¾ç, »ùÁ¾´àÀºÁ¾¾ç
  • adenomatoid odontogenic tumor
    »ù¸ð¾çÄ¡¾ÆÅ¿Á¾¾ç, »ù¸ð¾çÄ¡¾Æ¿øÀÎÁ¾¾ç
  • adrenal rest tumor
    ºÎ½ÅÀÜ·ùÁ¾¾ç
  • tumor bearing animal
    Á¾¾çµ¿¹°
  • benign tumor
    ¾ç¼ºÁ¾¾ç
  • blue tumor
    û»öÁ¾
  • carcinoid tumor
    Ä«¸£½Ã³ëÀ̵åÁ¾¾ç
  • tumor control
    Á¾¾ç¾ïÁ¦
  • tumor lymphnode metastasis classification
    Á¾¾ç¸²ÇÁÀýÀüÀ̺зù
  • desmoid tumor
    µ¥½º¸ðÀ̵åÁ¾¾ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • immunologic rejection
    ¸é¿ªÇÐÀû °ÅºÎ.
  • immunological rejection
    ¸é¿ªÇÐÀû°ÅºÎ
  • rejection
    °ÅºÎ (ËÞÜú)
  • rejection phenomenon
    °ÅÀýÇö»ó(ËÞï¾úÞßÚ).
  • rejection phenomenon
    °ÅÀýÇö»ó(ËÞï¾úÞßÚ).
  • rejection reaction
    °ÅÀý(¹ÝÀÀ)(ËÞï¾Úãëë).
  • rejection reaction
    °ÅÀý(¹ÝÀÀ)(ËÞï¾Úãëë).
  • rejection, allograft
    µ¿Á¾À̽Ä(Æí)°ÅºÎ(¹ÝÀÀ)
  • rejection, hypersensitivity to
    °ÅºÎ¿¡ ´ëÇÑ °ú¹Î(-¼º)
  • Chinese hamster ovary tumor cell
    Áß±¹ÇÔ½ºÅÍ ³­¼Ò¼¼Æ÷, CHO¼¼Æ÷
  • Dermoid tumor
    À¯ÇÇÁ¾
  • Granulosa cell tumor
    °ú¸³¸·¼¼Æ÷Á¾¾ç(Î¨Ø£Ø¯á¬øàðþåË)
  • Leydig cell tumor
    ·¹À̵ðÈ÷¼¼Æ÷Á¾¾ç
  • Schwann cell tumor
    ½´¹Ý¼¼Æ÷Á¾¾ç
  • TNF => tumor necrosis factor
    Á¾¾ç±«»çÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • homograft rejection
    µ¿Á¾ÀÌ½ÄÆí°ÅºÎ(¹ÝÀÀ)(¡­°ÅºÎ¹ÝÀÀ).
  • immunologic rejection
    ¸é¿ªÇÐÀû °ÅºÎ.
  • immunological rejection
    ¸é¿ªÇÐÀû°ÅºÎ
  • rejection
    °ÅºÎ (ËÞÜú)
  • rejection phenomenon
    °ÅÀýÇö»ó(ËÞï¾úÞßÚ).
  • rejection phenomenon
    °ÅÀýÇö»ó(ËÞï¾úÞßÚ).
  • rejection reaction
    °ÅÀý(¹ÝÀÀ)(ËÞï¾Úãëë).
  • rejection reaction
    °ÅÀý(¹ÝÀÀ)(ËÞï¾Úãëë).
  • rejection, allograft
    µ¿Á¾À̽Ä(Æí)°ÅºÎ(¹ÝÀÀ)
  • rejection, hypersensitivity to
    °ÅºÎ¿¡ ´ëÇÑ °ú¹Î(-¼º)
  • specimen rejection
    °Ëü°ÅÀý
  • transplant rejection
    À̽İźÎ(ì¹ãÕËÞÜú).
  • tubular rejection fraction ratio
    ½Å¼¼´¢°ü°ÅºÎºÐȹ·ü.
  • adeno-associated virus
    ¾Æµ¥³ë(¹ÙÀÌ·¯½º) ÀÇÁ¸ ¹ÙÀÌ·¯½º
  • adeno-associated virus
    ¾Æµ¥³ë°ü·Ã(¡­Î¼æá) ¹ÙÀÌ·¯½º.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • tumor virus
    Á¾¾ç(ðþåË)¹ÙÀÌ·¯½º
  • antigen
    Ç׿ø(ù÷ê«)
  • antigen binding capacity
    Ç׿ø °áÇÕ´É(ù÷ê«Ì¿ùêÒö)
  • antigen binding site
    Ç׿ø°áÇÕ(ù÷ê«Ì¿ùê)ÀÚ¸®
  • antigen presenting cell
    Ç׿øº¸À¯¼¼Æ÷(ù÷ê«ÜÁêóá¬øà)
  • antigen-antibody complex
    Ç׿øÇ×ü º¹ÇÕü(ù÷ê«ù÷ô÷ ÜÜùêô÷)
  • antigen-antibody lattice
    Ç׿øÇ×ü °ÝÀÚ(ù÷ê«ù÷ô÷ Ì«í­)
  • antigen-antibody reaction
    Ç׿øÇ×ü ¹ÝÀÀ(ù÷ê«ù÷ô÷Úãëë)
  • antigen-binding fragment
    Ç׿ø°áÇÕ(ù÷ê«Ì¿ùê) Á¶°¢
  • antigen-excess zone
    Ç׿ø°úÀ× ±¸¿ª(ù÷ê«Î¦í¥Ï¡æ´)
  • Australia antigen
    ¿À½ºÆ®¶ö¸®¾Æ Ç׿ø (ù÷ê«)
  • Boivin antigen
    º¸¿Í¹æ Ç׿ø(ù÷ê«)
  • complete antigen
    ¿ÏÀüÇ׿ø(èÇîïù÷ê«)
  • conjugated antigen
    Æ÷ÇÕÇ׿ø(øÙùêù÷ê«)
  • cross-reacting antigen
    ±³Â÷¹ÝÀÀ Ç׿ø(Îßó©Úãëëù÷ê«)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • hormone dependent tumor
    È£¸£¸óÀÇÁ¸¼ºÁ¾¾ç
  • hormone producing tumor
    È£¸£¸ó»ý»êÁ¾¾ç
  • malignant tumor
    ¾Ç¼ºÁ¾¾ç
  • mediastinal tumor
    Á¾°ÝÁ¾¾ç
  • mesenteric tumor
    Àå°£¸·Á¾¾ç
  • metastatic tumor
    ÀüÀ̼ºÁ¾¾ç
  • mixed tumor
    È¥ÇÕÁ¾¾ç
  • mucoepidermoid tumor
    Á¡¾×Ç¥ÇǾçÁ¾¾ç
  • mucous tumor
    Á¡¾×Á¾
  • nasopharyngeal tumor
    ºñÀεÎÁ¾¾ç
  • neurogenic tumor
    ½Å°æ(¿ø)¼ºÁ¾¾ç
  • nonfunctioning tumor
    ºñ±â´É¼ºÁ¾¾ç
  • odontogenic tumor
    Ä¡(¿ø)¼ºÁ¾¾ç
  • ovarian tumor
    ³­¼ÒÁ¾¾ç
  • papillary tumor
    À¯µÎ»ó Á¾¾ç
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
SSAA sicca syndrome associated antigen A; Sjogren syndrome-associated antigen A; syringomyelia secondary ...
CEA Carcino-Embryonic Antigen [HP 1825-6]
  ; Oncofetal Antigens
  ; Glycopro...
TA alkaline tuberculin; arterial tension; axillary temperature; tactile afferent; Takayasu arteritis; t...
HLA histocompatibility leukocyte antigen; histocompatibility locus antigen; homologous leukocyte antibod...
AFP Alpha(¥á) Feto-Protein [HP 1826, 1858, 1859, 2265]
  ; Oncofetal Antigens
 &nbs...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ACR Acute cellular rejection
ARE Acute rejection episodes
AVR Acute vascular rejection
CR Chronic rejection
DXR Delayed xenograft rejection
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • skin-associated lymphoid tissue
    ÇǺΠ¿¬°ü ¸²ÇÁ Á¶Á÷°è
  • accessible antigen
    Á¢±Ù °¡´É Ç׿ø, ±ÙÁ¢ Ç׿ø
  • antigen adjuvant
    Ç׿ø ¾ÆÁê¹ÝÆ®, Ç׿ø º¸°­Á¦
  • antigen antibody complex
    Ç׿ø Ç×ü º¹ÇÕü
    Ç׿ø°ú Ç×ü°¡ °áÇÕÇÑ °Í. ¸é¿ª º¹ÇÕü¶ó°íµµ ÇÑ´Ù. Ç×ü´Â Ç׿ø°ú °áÇÕÇÏ¿© º¹ÇÕü¸¦ ¸¸µé¸é º¸Ã¼ Ȱ¼ºÈ­ ÀÛ¿ëÀ» °¡Áö°Ô µÈ´Ù. ±×·¡¼­ »ýü ³»¿¡¼­ ¸é¿ª º¹ÇÕü°¡ Çü¼ºµÇ¸é ±× ÁÖº¯¿¡¼­ ºÎü°¡ Ȱ¼ºÈ­µÇ¾î ¿°Áõ¹ÝÀÀÀ» ¹ß»ý½ÃŰ´Â ¼ÀÀÌ´Ù. Ç׿ø Ç×ü º¹ÇÕü´Â ħ°­¼ºÀÇ °ÍÀ¸·Î µÇ±â ½±´Ù. µû¶ó¼­ Ç׿øÀÇ Ä§ÀÔ ºÎÀ§¿¡ ¿°Áõ¹ÝÀÀÀÌ »ý±â±â ½±´Ù.
  • antigen antibody reaction
    Ç׿ø Ç×ü ¹ÝÀÀ
  • antigen binding cell
    Ç׿ø °áÇÕ ¼¼Æ÷
    Ç׿ø¿¡ ´ëÇÑ Æ¯ÀÌÀûÀÎ °áÇձ⸦ ¼¼Æ÷ Ç¥¸é¿¡ °¡Áö°í ÀÖÀ¸¸ç Ç׿øÀ» ¼¼Æ÷ Ç¥¸é¿¡ °áÇÕ½ÃŰ´Â ´É·ÂÀ» °¡Áø ¼¼Æ÷. B ¼¼Æ÷ ¹× ÀϺÎÀÇ T ¼¼Æ÷°¡ Ç׿ø °áÇÕ ¼¼Æ÷¿¡ ÇØ´çµÈ´Ù. À̵éÀÇ ¸²ÇÁ±¸ÀÇ ¼¼Æ÷ Ç¥¸é¿¡ Ç׿øÀÌ °áÇյǾî ÀÖ´Â »óŸ¦ °¢Á¾ ¹æ¹ýÀ¸·Î È®ÀÎÇÒ ¼ö ÀÖ´Ù. Ç׿øÀ» ¹æ»ç¼º ¹°Áú·Î Ç¥ÁöÇØ µÎ°í autoradiogra
  • antigen binding fragment
    Ç׿ø °áÇÕ ºÎÀ§
  • antigen binding site
    Ç׿ø °áÇÕ ºÎÀ§
    ¸é¿ª ±Û·ÎºÒ¸°ÀÇ 3Â÷ ±¸Á¶»ó H ¼â¿Í L ¼âÀÇ °¡º¯¿µ¿ª¿¡¼­ ±¸¼ºµÇ¾î ÀÖ´Â Ç׿ø°ú °áÇÕÇÏ´Â ºÎÀ§.
  • antigen combining site
    Ç׿ø °áÇÕºÎ
  • antigen detection
    Ç׿ø °ËÃâ
  • antigen drift
    Ç׿ø¼Ò º¯ÀÌ
  • antigen excess
    Ç׿ø °úÀ×
    ħ°­ ¹ÝÀÀ µî ÃÖÀûºñ¿¡¼­ ¹ÝÀÀÀÌ Àß °üÂûµÇ´Â °æ¿ì Ç׿øÀÇ ¾çÀÌ Áö³ªÄ¡°Ô ¸¹À¸¸é ¹Ý´ë·Î ¹ÝÀÀÀÌ ¾àÇØÁö°í °üÂûÀÌ °¡´ÉÇÑ ¹ÝÀÀÀÌ »ý±æ ¶§±îÁöÀÇ ½Ã°£ÀÌ ±æ¾îÁø´Ù. ÀÌ¿Í °°ÀÌ Ç׿øÀÌ °úÀ×µÇ¾î ¹ÝÀÀÀÌ °üÂûµÇÁö ¾Ê°Ô µÇ´Â °æ¿ì Ç׿ø °úÀ׿¡ ÀÇÇÑ ¹ÝÀÀÀÇ ¾ïÁ¦Çϰí ÇÑ´Ù. Ç׿ø Ç×ü º¹ÇÕü´Â Ç׿ø °úÀ×ÀÎ °æ¿ì¿¡´Â °¡¿ë¼ºÀÌ µÈ´Ù.
  • antigen mimicry
    Ç׿ø À¯»ç¼º
  • antigen presentation
    Ç׿ø Á¦°ø, Ç׿ø Àü´Þ, Ç׿ø Á¦½Ã
  • antigen processing
    Ç׿ø ó¸®
    Ç׿øÀÌ Ç׿ø Á¦½Ã ¼¼Æ÷¿¡ ÀÇÇÏ¿© Æ÷ÃËµÇ°í ³ª¼­ B ¼¼Æ÷, T ¼¼Æ÷¿¡ Ç׿øÀÌ Á¦½ÃµÇ±â±îÁöÀÇ °úÁ¤À» ¸»ÇÑ´Ù. ÀÌ °úÁ¤¿¡´Â Ç׿øÀÇ Å½½Ä, Ç׿øÀÇ ´ÜÆíÈ­ ȤÀº Ç׿ø °áÁ¤±â±îÁöÀÇ ºÐÇØ 󸮰¡ Æ÷ÇԵȴÙ.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
graft rejection <haematology, immunology> When donated bone marrow infused during a bone marrow transplant is rejected by the patients body or does not take.
(16 Dec 1997)
chronic allograft rejection Immunologically mediated damage to the allograft, typically a kidney allograft, manifested by diffuse interstitial fibrosis glomerular changes, typically membranous and sclerotic in nature, as well as intimal fibrosis of the blood vessels with tubular atrophy and loss of tubular structures.
(05 Mar 2000)
chronic rejection A transplant rejection occurring after a few or many months, mainly from persisting serum antibody action.
(05 Mar 2000)
primary rejection A rejection occurring more than seven days after transplantation, mainly from a cellular immune response.
(05 Mar 2000)
second set rejection An accelerated rejection of a transplant that occurs when an individual has been previously sensitised to the graft.
(05 Mar 2000)
hyperacute rejection A rejection that usually develops in less than one hour from the implantation of a vascular graft, a form of antibody-mediated, usually irreversible damage to a transplanted organ, particularly the kidney, manifested predominantly by diffuse thrombotic lesions, usually confined to the organ itself and only rarely disseminated, for skin allograft rejection of this type, see white graft.
(05 Mar 2000)
first-set rejection Allograft transplantation between two organisms not previously sensitised to the graft tissue. Necrosis of the graft usually occurs within 10 days of transplantation.
(05 Mar 2000)
adeno-associated virus <virology> A genus of viruses in the family Parvoviridae which are all defective viruses (unable to replicate by themselves) and depend on the co-infection of their host cell by other, nondefective viruses to help them replicate.
(09 Oct 1997)
aids-associated nephropathy Renal syndrome in human immunodeficiency virus-infected patients characterised by nephrotic syndrome, severe proteinuria, focal and segmental glomerulosclerosis with distinctive tubular and interstitial changes, enlarged kidneys, and peculiar tubuloreticular structures. The syndrome is distinct from heroin-associated nephropathy as well as other forms of kidney disease seen in HIV-infected patients.
(12 Dec 1998)
antigens, tumour-associated, carbohydrate Carbohydrate antigens expressed by malignant tissue. They are useful as tumour markers and are measured in the serum by means of a radioimmunoassay employing monoclonal antibodies.
(12 Dec 1998)
associated Joined as a companion; brought into association; accompanying; combined.
<physiology> Associated movements, consensual movements which accompany voluntary efforts without our consciousness.
Source: Websters Dictionary
(01 Mar 1998)
associated antagonist One of two muscles or groups of muscles which pull in nearly opposite directions, but which, when acting together, move the part in a path between their diverging lines of action.
(05 Mar 2000)
associated macrophage A mature macrophage in an active metabolic state that is cytotoxic to tumour/target cells, usually following exposure to certain cytokines.
(05 Mar 2000)
associated movements Normal involuntary limp movements that accompany voluntary movement, e.g., arm swing with walking.
(05 Mar 2000)
p60 tumour necrosis factor receptor-associated kinase <enzyme> Interacts with and causes phosphorylation of the cytoplasmic domain of the tnf receptor
Registry number: EC 2.7.10.-
Synonym: p60 tnf receptor-associated kinase, p60-trak
(26 Jun 1999)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á